Biological agents are now increasingly used in the treatment of psoriasis, mainly tumor necrosis factor antagonists, including Iscriptive, infliximab, adalimumab, etc., and interleukin 17 antagonists, such as secukizumab. Their effects are still more obvious compared with traditional drugs, such as cyclosporine, avidin and methotrexate, and they are administered at longer intervals and in an easier way. They are mainly used to treat arthritic psoriasis, but also plaque psoriasis and erythrodermic disease. However, biologics are more expensive and may also lead to serious infections and should be avoided by patients with tuberculosis.